Trial Profile
A retrospective study to evaluate effect of early switching to ranibizumab or aflibercept in patients with diabetic macular edema who did not show any response to bevacizumab therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 26 Jul 2017 New trial record